Predict your next investment

Asset/Investment Management
FINANCIAL | Asset/Financial Management
oaktreecapital.com

See what CB Insights has to offer

Investments

105

Portfolio Exits

46

Funds

108

Partners & Customers

9

Service Providers

3

About Oaktree Capital Management

Oaktree Capital Management is an American global asset management firm specializing in alternative investment strategies. The firm emphasizes an opportunistic, value-oriented and risk-controlled approach to investments in credit, private equity, real assets and listed equities.

Oaktree Capital Management Headquarter Location

333 South Grand Ave 28th Floor

Los Angeles, California, 90071,

United States

213-830-6300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Oaktree Capital Management Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oaktree Capital Management Rank

Research containing Oaktree Capital Management

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Oaktree Capital Management in 3 CB Insights research briefs, most recently on Jul 14, 2021.

Latest Oaktree Capital Management News

MESOBLAST : AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILITY - Form 6-K

Nov 26, 2021

11/26/2021 | 06:20am EST Message : MESOBLAST AND OAKTREE CAPITAL ENTER INTO REFINANCING AND EXPANSION OF SENIOR DEBT FACILITY Melbourne, Australia; November 22, and New York, USA; November 21, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. ("Oaktree"). Mesoblast drew the first tranche of US$60 million on closing, with proceeds being used to repay the outstanding balance of the existing senior debt facility with Hercules Capital, Inc. Up to an additional US$30 million may be drawn on or before December 31, 2022, subject to certain milestones. The facility has a three-year interest only period, at a rate of 9.75% per annum, after which time 40% of the principal amortizes over two years and a final payment due November 2026. Oaktree will also receive warrants to purchase 1,769,669 American Depositary Shares (ADSs)1 at US$7.26 per ADS, a 15% premium to the 30-day VWAP. The warrants may be exercised within 7 years of issuance. "We are pleased to have leading global investment management firm Oaktree as our new financing partner as we focus on bringing our first product to the US market. Oaktree has a demonstrated partnership approach to innovative companies, making it an excellent fit to support Mesoblast's commercial growth strategy over the next five years," said Silviu Itescu, Chief Executive of Mesoblast. Aman Kumar, Co-Portfolio Manager of Life Sciences Lending at Oaktree said, "We are delighted to partner with Mesoblast at this point in its development. We recognize the quality of the portfolio and the significant near-term milestones that could help the company successfully commercialize its first product in the US." Cantor Fitzgerald & Co. acted as exclusive arranger and financial advisor to Mesoblast in this transaction. About Mesoblast Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Rexlemestrocel-L is in development for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast's licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast 1 The warrants will be issued under a prospectus to be lodged with ASIC under which the warrants will be offered to Oaktree. The agreement to issue the warrants is subject to approval of Mesoblast shareholders if required at the time of issue for the purposes of the 15% placement limit in Listing Rule 7.1. Mesoblast Limited Oaktree is a leader among global investment managers specializing in alternative investments, with $158 billion in assets under management as of September 30, 2021. The firm emphasizes an opportunistic, value-oriented and risk-controlled approach to investments in credit, private equity, real assets and listed equities. The firm has over 1,000 employees and offices in 19 cities worldwide. For additional information, please visit Oaktree's website at http://www.oaktreecapital.com/ Forward-Looking Statements This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward- looking statements include, but are not limited to, statements about: Mesoblast's ability to meet the necessary conditions and milestones to draw down on the facility; the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact: Corporate Communications / Investors

Oaktree Capital Management Investments

105 Investments

Oaktree Capital Management has made 105 investments. Their latest investment was in Thrasio as part of their Series D on October 10, 2021.

CBI Logo

Oaktree Capital Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/25/2021

Series D

Thrasio

$1,000M

No

6

10/14/2021

Debt

OTG Management

$1,250M

Yes

2

10/13/2021

Corporate Minority

Interfirst

$175M

Yes

MFA Financial, StoicLane, and Undisclosed Investors

3

9/29/2021

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

9/21/2021

Debt - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2021

10/14/2021

10/13/2021

9/29/2021

9/21/2021

Round

Series D

Debt

Corporate Minority

Private Equity

Debt - III

Company

Thrasio

OTG Management

Interfirst

Subscribe to see more

Subscribe to see more

Amount

$1,000M

$1,250M

$175M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

MFA Financial, StoicLane, and Undisclosed Investors

Sources

6

2

3

10

10

Oaktree Capital Management Portfolio Exits

46 Portfolio Exits

Oaktree Capital Management has 46 portfolio exits. Their latest portfolio exit was Endeavor on April 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/29/2021

IPO

$991

1

1/27/2021

IPO

$991

1

12/10/2020

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

4/29/2021

1/27/2021

12/10/2020

00/00/0000

00/00/0000

Exit

IPO

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Oaktree Capital Management Acquisitions

82 Acquisitions

Oaktree Capital Management acquired 82 companies. Their latest acquisition was Sanlam on September 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/2021

$991

Acquired

4

8/6/2021

Acq - Fin

1

8/3/2021

$991

Acq - Fin

2

6/7/2021

Shareholder Liquidity

Subscribe to see more

$99M

Subscribe to see more

10

3/16/2021

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/20/2021

8/6/2021

8/3/2021

6/7/2021

3/16/2021

Investment Stage

Shareholder Liquidity

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Total Funding

$99M

$99M

Note

Acquired

Acq - Fin

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Oaktree Capital Management Fund History

108 Fund Histories

Oaktree Capital Management has 108 funds, including Oaktree Opportunities Fund XI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/16/2021

Oaktree Opportunities Fund XI

$15,900M

1

11/30/2020

Oaktree Employee Investment Fund

$0.23M

8

8/20/2020

PE Premier Oaktree Opportunities XI Offshore Feeder

$68.82M

1

8/5/2020

Oaktree Opportunities Fund XI Feeder 3 (Cayman)

Subscribe to see more

$99M

10

7/22/2020

Oaktree Mezzanine Fund V Feeder (ICI) (Cayman)

Subscribe to see more

$99M

10

Closing Date

11/16/2021

11/30/2020

8/20/2020

8/5/2020

7/22/2020

Fund

Oaktree Opportunities Fund XI

Oaktree Employee Investment Fund

PE Premier Oaktree Opportunities XI Offshore Feeder

Oaktree Opportunities Fund XI Feeder 3 (Cayman)

Oaktree Mezzanine Fund V Feeder (ICI) (Cayman)

Fund Type

Subscribe to see more

Subscribe to see more

Status

Amount

$15,900M

$0.23M

$68.82M

$99M

$99M

Sources

1

8

1

10

10

Oaktree Capital Management Partners & Customers

9 Partners and customers

Oaktree Capital Management has 9 strategic partners and customers. Oaktree Capital Management recently partnered with American Industrial Partners on February 2, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

2/17/2021

Partner

American Industrial Partners

United States

American Industrial Partners and Oaktree Announce Strategic Partnership in Rand Logistics

`` On behalf of management and Rand Logistics , Inc. 's employees , we could not have anticipated a better addition to an already excellent partnership with AIP than Oaktree Capital Management , '' said Dave Foster , CEO of Rand Logistics , Inc. .

1

10/29/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

6/23/2017

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

4/22/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

3/31/2016

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/17/2021

10/29/2018

6/23/2017

4/22/2016

3/31/2016

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

American Industrial Partners

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

American Industrial Partners and Oaktree Announce Strategic Partnership in Rand Logistics

`` On behalf of management and Rand Logistics , Inc. 's employees , we could not have anticipated a better addition to an already excellent partnership with AIP than Oaktree Capital Management , '' said Dave Foster , CEO of Rand Logistics , Inc. .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Oaktree Capital Management Service Providers

4 Service Providers

Oaktree Capital Management has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Fin

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Fin

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Oaktree Capital Management Team

45 Team Members

Oaktree Capital Management has 45 team members, including current Chief Executive Officer, Jay Wintrob.

Name

Work History

Title

Status

Jay Wintrob

Chief Executive Officer

Current

Bruce A Karsh

President

Current

David Kirchheimer

Chief Financial Officer

Current

Federico Canciani

Senior Vice President

Current

Robert C. LaRoche

Senior Vice President

Current

Name

Jay Wintrob

Bruce A Karsh

David Kirchheimer

Federico Canciani

Robert C. LaRoche

Work History

Title

Chief Executive Officer

President

Chief Financial Officer

Senior Vice President

Senior Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.